Natixis Apellis Pharmaceuticals, Inc. Transaction History
Natixis
- $22 Billion
- Q2 2025
A detailed history of Natixis transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Natixis holds 90,666 shares of APLS stock, worth $2.17 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
90,666
Previous 655,027
86.16%
Holding current value
$2.17 Million
Previous $14.3 Million
89.05%
% of portfolio
0.01%
Previous 0.08%
Shares
15 transactions
Others Institutions Holding APLS
# of Institutions
295Shares Held
132MCall Options Held
2.97MPut Options Held
623K-
Avoro Capital Advisors LLC New York, NY12.2MShares$292 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$284 Million17.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$243 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.75MShares$233 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.98MShares$215 Million0.03% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.63B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...